Equities researchers at Royal Bank Of Canada initiated coverage on shares of Ra Pharmctl Inc (NASDAQ:RARX) in a research report issued to clients and investors on Thursday. The firm set an “outperform” rating on the stock.

RARX has been the topic of several other research reports. Jefferies Group LLC restated a “buy” rating and set a $25.00 price objective on shares of Ra Pharmctl in a research note on Thursday, June 1st. Zacks Investment Research upgraded Ra Pharmctl from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research note on Wednesday, May 17th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $27.00.

Ra Pharmctl (NASDAQ:RARX) traded up 5.84% on Thursday, reaching $14.87. The company’s stock had a trading volume of 119,396 shares. Ra Pharmctl has a 52 week low of $12.05 and a 52 week high of $24.12. The firm’s 50 day moving average price is $14.25 and its 200-day moving average price is $18.93. The company’s market capitalization is $336.20 million.

Ra Pharmctl (NASDAQ:RARX) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). On average, equities analysts predict that Ra Pharmctl will post ($2.33) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Royal Bank Of Canada Begins Coverage on Ra Pharmctl Inc (RARX)” was originally published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/14/royal-bank-of-canada-begins-coverage-on-ra-pharmctl-inc-rarx.html.

In related news, major shareholder Bioventures Ltd Novartis sold 56,420 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $21.29, for a total value of $1,201,181.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 14.50% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in RARX. American International Group Inc. bought a new stake in shares of Ra Pharmctl during the 1st quarter worth $102,000. TIAA CREF Investment Management LLC boosted its stake in shares of Ra Pharmctl by 97.0% during the 1st quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after acquiring an additional 3,859 shares in the last quarter. Alliancebernstein L.P. bought a new stake in shares of Ra Pharmctl during the 2nd quarter worth $195,000. Wells Fargo & Company MN boosted its stake in shares of Ra Pharmctl by 151.8% during the 1st quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock worth $202,000 after acquiring an additional 5,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Ra Pharmctl by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after acquiring an additional 2,543 shares in the last quarter. 66.26% of the stock is owned by institutional investors and hedge funds.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.